Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer.
Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE.
Chesner LN, et al. Among authors: ashworth a.
Cancer Discov. 2024 Dec 5. doi: 10.1158/2159-8290.CD-24-0559. Online ahead of print.
Cancer Discov. 2024.
PMID: 39652470